These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2203309)

  • 21. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms.
    Chiu CC; Lin TC; Wu RX; Yang YS; Hsiao PJ; Lee Y; Lin JC; Chang FY
    J Microbiol Immunol Infect; 2017 Dec; 50(6):879-885. PubMed ID: 28087318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftazidime in clinical practice.
    Alestig K; Eilard T; Norrby R; Svensson R; Trollfors B; Brorson JE
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():111-4. PubMed ID: 6225759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of results of world-wide clinical trials with cefadroxil.
    Santella PJ; Tanrisever B; Berman E
    J Int Med Res; 1978; 6(6):441-51. PubMed ID: 363481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefepime versus ceftazidime in the treatment of lower respiratory tract infections.
    Aufiero A; Sturani C; Zanon P; Marruchella A; Michetti G; Nicolin E; Sella D; Goglio A; Silleni M; La Regina A
    J Chemother; 1997 Jun; 9(3):213-8. PubMed ID: 9210005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients.
    Jones ME; Karlowsky JA; Draghi DC; Thornsberry C; Sahm DF; Bradley JS
    Eur J Clin Microbiol Infect Dis; 2004 Jun; 23(6):445-55. PubMed ID: 15156358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care.
    Gouin F; Papazian L; Martin C; Albanese J; Durbec O; Domart Y; Veyssier P; Leroy J; Grès JJ; Rollin C
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():205-14. PubMed ID: 8150764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
    Smith BR
    Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of cefepime in the treatment of serious bacterial infections in hospitalized adult patients.
    Sheng WH; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2000 Jun; 33(2):109-14. PubMed ID: 10917881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefepime: a new fourth-generation cephalosporin.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis.
    Arguedas AG; Stutman HR; Zaleska M; Knupp CA; Marks MI; Nussbaum E
    Am J Dis Child; 1992 Jul; 146(7):797-802. PubMed ID: 1496945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections.
    Therasse DG
    Am J Med; 1992 Jun; 92(6A):20S-25S. PubMed ID: 1621742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.
    Tsuji M; Takema M; Miwa H; Shimada J; Kuwahara S
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2507-12. PubMed ID: 12878512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections.
    Léophonte P; Bertrand A; Nouvet G; Muir JF; Lucht F; Delaval P; Depierre A; Hughes F; Ulmer M; Grès JJ
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():165-73. PubMed ID: 8150760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
    Kessler RE; Bies M; Buck RE; Chisholm DR; Pursiano TA; Tsai YH; Misiek M; Price KE; Leitner F
    Antimicrob Agents Chemother; 1985 Feb; 27(2):207-16. PubMed ID: 3885849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefepime as treatment for osteomyelitis and other severe bacterial infections.
    Jauregui L; Matzke D; Scott M; Minns P; Hageage G
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():141-9. PubMed ID: 8150758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
    Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group.
    Zervos M; Nelson M
    Antimicrob Agents Chemother; 1998 Apr; 42(4):729-33. PubMed ID: 9559773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evaluation of ceftriaxone.
    File TM; Tan JS; Salstrom SJ
    Clin Ther; 1984; 6(5):653-61. PubMed ID: 6090021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a new cephalosporin antibiotic, cephapirin.
    Wiesner P; MacGregor R; Bear D; Berman S; Holmes K; Turck M
    Antimicrob Agents Chemother; 1972 Apr; 1(4):303-9. PubMed ID: 4208896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.